Alfonso Chang, CFA is a Managing Director of Relativity Healthcare Partners (“RHCP”), an investment group dedicated to providing growth capital to emerging healthcare companies. Examples of investments by RHCP affiliated funds include BioAnalytix, Inc., BeneStream, OrphoMed, and MD Revolution, Inc. Concurrently, Alfonso is a Managing Director of The AC3 Group, a boutique strategy consultancy. As a strategist, he advises mainly healthcare companies on financial and strategic topics, including alliances, corporate finance, deal structuring, lifecycle management, marketing, product development /management, and strategic planning. For over fifteen years, he has provided counsel to leading global companies, and he has worked with products at various stages of development (clinical to commercial) and sizes (niche to blockbuster). For RHCP, he uses his expertise to identify and structure investment opportunities and to provide strategic guidance to portfolio companies. Alfonso serves on the board of directors of BioAnalytix and Health Republic Insurance of New York. Alfonso is a holder of the right to use the Chartered Financial Analyst designation, has an MBA from the University of Michigan, and has a BSE in chemical engineering from the University of Pennsylvania. He co-authored with others, including Dr. Lawton Burns, a report on the biopharmaceutical sector’s impact to the US economy. Alfonso has been invited as a guest speaker and judge, including University of Michigan’s graduate course entitled Business of Biology and Startup Weekend NYC: Health and Fitness Edition, respectively. He is a member of the New York Society of Security Analysts.